PRE Stock Forecast & Price Target

Prenetics Global is attractive fundamentally because IM8 has scaled with exceptional speed, reaching nearly $200M of ARR by May 31 and driving 1Q26 revenue of $36M, up about 333% year over year, with preliminary June revenue near $17M lifting FY26 guidance to $210M-$220M. The company’s growth is supported by a $1 billion CVF financing that funds up to 70% of IM8 marketing spend without dilution, while ~$140M of cash and equivalents, later supplemented by asset-sale proceeds, reduces balance-sheet risk and extends runway. Strong unit economics and brand quality further support the outlook, including LTV/CAC of 3:1, quarterly subscriptions that improved AOV to $240, 64% gross margin, and clinically validated products backed by expanding influencer, channel, and product-line advantages.

Prenetics Global is under pressure because its growth model still depends on very high sales and marketing spend, with S&M/revenue expected to stay above 60% even as FY2026 IM8 revenue is modeled at $204M and adj. EBITDA loss is projected at ($26.5M). The business is also exposed to rising customer acquisition costs as it shifts toward longer-duration quarterly subscribers, and any deterioration in digital ad rates, platform algorithms, or privacy rules could prevent LTV/CAC from staying near 3:1. As a global DTC operator, it also faces structurally heavy freight, warehousing, packaging, last-mile delivery, and fulfillment costs, making profitability difficult without tighter expense control.